HIV protease inhibitors stimulate hepatic triglyceride synthesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 12, 2000, Pages 2625-2629

  Lenhard, James M ^a   Croom, Dallas K ^a   Weiel, James E ^a   Winegar, Deborah A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

HIV; Hypertriglyceridemia; Liver; Protease inhibitor; Retinoid

Indexed keywords

AMPRENAVIR; CHOLESTEROL; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID SYNTHASE; GLUCOSE; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0033675321     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.12.2625     Document Type: Article

References (24)

1. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
2. HIV-associated lipodystrophy syndrome
3. Fat distribution and metabolic changes in patients with HIV infection
4. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
5. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
6. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
7. The next generation of human immunodeficiency virus protease inhibitors: Targeting viral resistance
8. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: The Swiss HIV Cohort Study
9. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
10. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
11. Marked hyperlipidemia on ritonavir therapy
12. Pharmacokinetic (PK) drug interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple, oral dosing
13. Influence of diet and genetics on metabolic abnormalities in mice treated with HIV protease inhibitons
14. Dietary fat alters HIV proteas inhibitor-induced metabolic abnormalities in mice
15. Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor
16. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
17. The effect of a non-ionic detergent (Triton WR 1339) on the removal of triglyceride fatty acids from the blood of the rat
18. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL
19. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor: Contribution to the hypertriglyceridemic action of retinoids
20. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
21. Stimulation of vitamin AJ acid signaling by the HIV protease inhibitor indinavir
22. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidemia and insulin resistance
23. Drug interaction of isotretinoin and protease inhibitors: Support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy?
24. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: A 5-year cohort study